Author | Howard A. Burris, III, MD | OncLive

Author | Howard A. Burris, III, MD

Articles

Dr. Burris on the Potential of PARP Inhibitors in TNBC

October 24, 2017

Video

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the potential of PARP inhibitors in patients with triple negative breast cancer (TNBC).

x